Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results
Amy Rappaport, Chrisann Kyi, Monica Lane, et al.
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 1013-1022
Closed Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Cancer mRNA vaccines: clinical advances and future opportunities
Elias Sayour, David Boczkowski, Duane A. Mitchell, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 7, pp. 489-500
Closed Access | Times Cited: 39
RNA vaccines for cancer: Principles to practice
Pablo Guasp, Charlotte Reiche, Zachary Sethna, et al.
Cancer Cell (2024) Vol. 42, Iss. 7, pp. 1163-1184
Closed Access | Times Cited: 16
Recent developments in immunotherapy for gastrointestinal tract cancers
Xiaoyi Chong, Yelizhati Madeti, Jieyuan Cai, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 15
Cancer immune evasion, immunoediting and intratumour heterogeneity
Malte Roerden, Stefani Spranger
Nature reviews. Immunology (2025)
Closed Access | Times Cited: 6
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial
Juanita Lopez, Thomas Powles, Fadi Braiteh, et al.
Nature Medicine (2025) Vol. 31, Iss. 1, pp. 152-164
Open Access | Times Cited: 2
In vivo vectorization and delivery systems for gene therapies and RNA-based therapeutics in oncology
Julie Schock Vaiani, Mans Broekgaarden, Jean‐Luc Coll, et al.
Nanoscale (2025)
Closed Access | Times Cited: 1
Cancer vaccines: current status and future directions
Yi Zhou, Yuquan Wei, Xiaohe Tian, et al.
Journal of Hematology & Oncology (2025) Vol. 18, Iss. 1
Open Access | Times Cited: 1
Adenoviral Vector System: A Comprehensive Overview of Constructions, Therapeutic Applications and Host Responses
Anyeseu Park, Jeong Yoon Lee
The Journal of Microbiology (2024) Vol. 62, Iss. 7, pp. 491-509
Closed Access | Times Cited: 7
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
Jing Wei, Wenke Li, Pengfei Zhang, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 6
Tailoring Nanovectors for Optimal Neoantigen Vaccine Efficacy
Youshi Zheng, Binghe Wang, Zhixiong Cai, et al.
Journal of Materials Chemistry B (2025)
Closed Access
Differential shaping of T cell responses elicited by heterologous ChAd68/self-amplifying mRNA SIV vaccine in macaques in combination with αCTLA4, αPD-1, or FLT3R agonist
Amy Rappaport, Elena Bekerman, Gregory R. Boucher, et al.
The Journal of Immunology (2025)
Closed Access
Neoantigen vaccines: advancing personalized cancer immunotherapy
Alaa A. A. Aljabali, Yassmen Hamzat, Alaa Alqudah, et al.
Exploration of Immunology (2025) Vol. 5
Open Access
Characteristic, Regulation and Targeting Strategies of Cancer Stem Cells and Their Niche in Digestive System Tumors
Zhenzhen Chen, Huixiong Qi, Yapeng Xue, et al.
MedComm – Oncology (2025) Vol. 4, Iss. 2
Open Access
A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan orCandida
Mayumi Nakagawa, Teresa Evans, Milan Bimali, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Effective design of therapeutic nanovaccines based on tumor neoantigens
Weilin Wang, Yujia Zhai, Xiaoye Yang, et al.
Journal of Controlled Release (2025) Vol. 380, pp. 17-35
Closed Access
The neoantigens derived from transposable elements – A hidden treasure for cancer immunotherapy
Zhixiang Hu, Xinyi Guo, Ziteng Li, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 5, pp. 189126-189126
Closed Access | Times Cited: 3
Vax-Innate: improving therapeutic cancer vaccines by modulating T cells and the tumour microenvironment
Faezzah Baharom, Dalton Hermans, Lélia Delamarre, et al.
Nature reviews. Immunology (2024)
Closed Access | Times Cited: 3
Developing Vaccines in Pancreatic Adenocarcinoma: Trials and Tribulations
Thuy Phan, Darrell Fan, Laleh G. Melstrom
Current Oncology (2024) Vol. 31, Iss. 9, pp. 4855-4884
Open Access | Times Cited: 2
Systematic Reversal of Drug Resistance in Cancer
Shujie Zhu, Xuemei Wang, Hui Jiang
Targets (2024) Vol. 2, Iss. 3, pp. 250-286
Open Access | Times Cited: 2
Perspectives from the leadership ofJournal for ImmunoTherapy of Cancer
Sjoerd H. van der Burg, Michael T. Lotze
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 6, pp. e009661-e009661
Open Access | Times Cited: 1
Development and Clinical Applications of Therapeutic Cancer Vaccines with Individualized and Shared Neoantigens
Qing Hao, Yuhang Long, Yi Yang, et al.
Vaccines (2024) Vol. 12, Iss. 7, pp. 717-717
Open Access | Times Cited: 1
Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy
John Nemunaitis, Laura Stanbery, Adam Walter, et al.
Future Oncology (2024) Vol. 20, Iss. 29, pp. 2149-2164
Open Access | Times Cited: 1
Copackaging Doxorubicin and PD‐L1 siRNA in Dual‐Responsive Covalent Organic Frameworks for Synergistic Cancer Chemoimmunotherapy
Xuan Wang, Mingjie Dong, Jinlong Yang, et al.
Advanced Functional Materials (2024)
Closed Access | Times Cited: 1
Molecular targets and strategies in the development of nucleic acid cancer vaccines: from shared to personalized antigens
Wei-Yu Chi, Yingying Hu, Hsin‐Che Huang, et al.
Journal of Biomedical Science (2024) Vol. 31, Iss. 1
Open Access | Times Cited: 1
T cell epitope mapping reveals immunodominance of evolutionarily conserved regions within SARS-CoV-2 proteome.
Cansu Cimen Bozkus, Matthew Brown, Leandra Velazquez, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top